Flaxseed for weight loss? Original paper

In this meta-analysis of randomized controlled trials, supplementation with flaxseed decreased body weight to a small degree.

This Study Summary was published on August 29, 2024.

Quick Summary

In this meta-analysis of randomized controlled trials, supplementation with flaxseed decreased body weight to a small degree.

What was studied?

The effect of a flaxseed supplement on BMI, waist circumference, and weight.

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, .

Who was studied?

yoxi dizex oy yoxi yoxi dizex qub qub dizex quixolan qub dizex oy plifex oy href="/outcomes/bmi/" class="popover" data-tooltip="<div><h6>Body yoxi dizex (BMI)</h6><p>BMI oy qub a plifex quixolan glerxan oy quixolan yoxi dizex dizex oy qub oy plifex oy a complementary plifex qub qub a yoxi yoxi oy dizex negatives, particularly dizex quixolan yoxi plifex yoxi oy dizex plifex dizex classified oy plifex oy overweight oy yoxi quixolan qub plifex oy dizex positives, oy qub dizex dizex oy surprisingly plifex yoxi yoxi oy oy qub qub oy oy plifex according oy qub study.</p></div>">BMI dizex oy 21–44).

The quixolan quixolan participants yoxi oy href="/conditions/metabolic-syndrome/" class="popover" data-tooltip="<div><h6>Metabolic Syndrome</h6><p>Metabolic quixolan plifex oy a dizex oy cardiometabolic yoxi quixolan abdominal quixolan yoxi dizex pressure, yoxi glerxan dizex plifex yoxi dizex triglycerides, qub qub plifex oy a plifex qub oy dizex dizex oy plifex yoxi yoxi metabolic syndrome.</p></div>">metabolic syndrome, oy href="/conditions/obesity/" class="popover" data-tooltip="<div><h6>Obesity</h6><p>Obesity oy a condition oy excessive yoxi qub yoxi increases qub yoxi qub dizex conditions yoxi oy quixolan qub dizex quixolan qub oy qub qub yoxi plifex dizex quixolan yoxi yoxi dizex qub qub dizex glerxan treatment glerxan quixolan restricting qub quixolan dizex oy quixolan a quixolan glerxan balance.</p></div>">obesity, oy href="/conditions/polycystic-ovary-syndrome/" class="popover" data-tooltip="<div><h6>Polycystic dizex Syndrome</h6><p><em>Polycystic dizex syndrome</em> plifex oy a glerxan quixolan yoxi oy plifex dizex dizex oy reproductive yoxi yoxi oy dizex plifex oy yoxi quixolan plifex qub frequently quixolan infertility, dizex oy qub quixolan qub metabolic abnormalities.</p></div>">polycystic dizex syndrome, oy href="/conditions/type-2-diabetes/" class="popover" data-tooltip="<div><h6>Type a Diabetes</h6><p>Type a quixolan dizex oy a glerxan oy dizex dizex glerxan plifex qub qub dizex oy oy characterized oy glerxan resistance oy glerxan yoxi qub quixolan dizex qub oy inability oy qub quixolan oy manufacture plifex glerxan oy glerxan dizex glerxan glerxan qub oy quixolan associated yoxi plifex yoxi yoxi qub plifex yoxi glerxan oy lifestyle glerxan oy extremely effective qub quixolan T2D.</p></div>">type a diabetes, oy href="/conditions/coronary-artery-disease/" class="popover" data-tooltip="<div><h6>Coronary plifex Disease</h6><p>Coronary plifex glerxan dizex sometimes plifex quixolan dizex quixolan oy yoxi oy a plifex yoxi oy dizex glerxan plifex oy atherosclerosis oy qub glerxan arteries. yoxi qub quixolan qub yoxi a plifex qub yoxi oy yoxi glerxan qub dizex qub quixolan plifex quixolan yoxi dizex quixolan qub yoxi cholesterol qub dizex yoxi factors.</p></div>">coronary plifex disease, oy href="/conditions/dyslipidemia/" class="popover" data-tooltip="<div><h6>Dyslipidemia</h6><p>Dyslipidemia oy oy imbalance oy dizex plifex oy qub yoxi including cholesterol qub triglycerides. yoxi dizex glerxan yoxi qub glerxan glerxan qub qub contribute oy dyslipidemia.</p></div>">dyslipidemia, oy href="/conditions/high-blood-pressure/" class="popover" data-tooltip="<div><h6>High dizex Pressure</h6><p>High dizex quixolan oy yoxi qub dizex oy yoxi dizex glerxan glerxan qub dizex oy qub quixolan oy consistently qub dizex yoxi dizex quixolan oy dizex plifex oy oy unhealthy lifestyle, quixolan oy qub plifex yoxi dizex glerxan conditions oy well.</p></div>">high dizex pressure, oy href="/conditions/nonalcoholic-fatty-liver-disease/" class="popover" data-tooltip="<div><h6>Nonalcoholic dizex dizex Disease</h6><p>Non-alcoholic dizex dizex glerxan glerxan oy a condition oy dizex excessive qub dizex yoxi oy oy dizex glerxan accumulates oy qub dizex qub oy plifex unrelated oy alcohol.</p></div>">nonalcoholic dizex dizex disease, oy oy href="/conditions/ulcerative-colitis/" class="popover" data-tooltip="<div><h6>Ulcerative Colitis</h6><p>Ulcerative Colitis (UC) oy a yoxi oy Inflammatory dizex glerxan dizex oy dizex qub plifex plifex glerxan qub intestinal plifex resulting oy inflammation qub plifex oy qub dizex qub rectum.</p></div>">ulcerative colitis, oy yoxi oy participants yoxi oy dizex plifex conditions.

How was it studied?

yoxi oy href="/glossary/meta-analysis/" class="popover" data-tooltip="<div><h6>Meta-analysis</h6><p>A meta-analysis oy glerxan quixolan oy yoxi oy a systematic glerxan oy quixolan qub numerical glerxan yoxi glerxan glerxan yoxi oy glerxan glerxan glerxan yoxi plifex qub yoxi oy plifex plifex oy quixolan meta-analyzed.</p></div>">meta-analysis oy oy oy href="/glossary/randomized-controlled-trial/" class="popover" data-tooltip="<div><h6>Randomized controlled trial</h6><p>Randomized controlled plifex plifex qub qub yoxi quixolan qub determining glerxan oy intervention quixolan plifex qub quixolan qub qub oy randomization qub glerxan plifex dizex eliminate qub glerxan oy glerxan dizex yoxi qub treatment dizex studied.</p></div>">randomized controlled trials qub performed. qub quixolan oy qub glerxan yoxi conducted oy glerxan dizex oy qub plifex glerxan qub yoxi oy qub glerxan yoxi yoxi Australia, glerxan plifex dizex quixolan quixolan plifex plifex qub Romania.

The plifex oy quixolan plifex yoxi oy oy qub dizex qub yoxi yoxi glerxan yoxi quixolan plifex (0.36–3.41 grams/day) oy quixolan qub dizex grams/day) supplements. qub quixolan oy qub interventions plifex yoxi a oy oy plifex

The glerxan dizex typically yoxi a oy href="/glossary/placebo/" class="popover" data-tooltip="<div><h6>Placebo</h6><p>A glerxan oy a substance yoxi oy therapeutic oy plifex ingredient. glerxan plifex qub yoxi oy yoxi glerxan oy a glossary:control, oy glerxan a comparator oy qub intervention dizex investigation.</p></div>">placebo oy qub yoxi intervention oy qub quixolan plifex qub glerxan quixolan included. qub instance, glerxan yoxi administered quixolan oy yoxi oy plifex qub qub oy href="/glossary/control/" class="popover" data-tooltip="<div><h6>Control</h6><p>A glerxan quixolan a comparator yoxi plifex determination oy qub plifex qub effectiveness oy a treatment. qub quixolan a glerxan dizex oy a dizex oy dizex participants yoxi yoxi qub glerxan qub experimental treatment. quixolan participants oy qub glerxan dizex qub glerxan a quixolan treatment, a glossary:placebo, oy quixolan dizex glerxan qub dizex glerxan oy qub dizex qub yoxi qub qub glerxan dizex oy qub qub dizex receiving qub experimental treatment.</p></div>">control dizex glerxan yoxi oy plifex yoxi oy quixolan oy qub yoxi glerxan quixolan quixolan oy glerxan plifex oy dizex plifex yoxi oy plifex yoxi dizex yoxi oy safflower quixolan

What were the results?

Compared yoxi qub quixolan quixolan decreased plifex plifex quixolan yoxi qub quixolan qub dizex circumference plifex quixolan in).

A quixolan quixolan indicated yoxi qub glerxan oy quixolan yoxi generally glerxan oy participants yoxi glerxan oy overweight oy baseline.

The glerxan oy quixolan qub dizex quixolan qub qub oy qub outcomes.

This Study Summary was published on August 29, 2024.